glp 1 gip dual agonist mechanism of action Understand GLP-1/GIP Tirzepatide and Its Effect on Current Weight Loss Therapy Dual and Triple Gut Peptide

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION6): a randomised, openlabel study

Abstract In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodiumglucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors

GLP-1 helps reduce this inflammatory burden, which is why people with autoimmune diseases often feel better when they lose even 510% of body weight

We also delve into the ongoing research along with future prospects of DPP-4 inhibitors, suggesting an increasing role for these agents in applications beyond the management of diabetes

The team first began work on the drug in 1999 (Cordes)

Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus